Breast Imaging

Which Imaging Best Assesses Axillary Response to Neoadjuvant Breast Cancer Chemo?

·

A 48-year-old patient with biopsy-proven, estrogen receptor-positive, HER2-negative invasive ductal carcinoma has just completed six months of neoadjuvant chemotherapy. At diagnosis, an ultrasound-guided biopsy confirmed metastatic disease in a level I axillary lymph node, which was marked with a clip. Now, as the multidisciplinary team plans for surgery, the central question is the status of her axilla. Has the chemotherapy cleared the nodal disease, allowing for less extensive surgery, or is residual disease present, necessitating a full axillary lymph node dissection? The next imaging study ordered will directly inform this critical surgical decision. This article details the American College of Radiology (ACR) Appropriateness Criteria for this exact scenario, explaining why a targeted study is the recommended next step. For this specific clinical question, the ACR has rated US axilla as Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies to a specific subset of patients with breast cancer: adults of any gender identity who have completed a full course of neoadjuvant systemic therapy (NST). The key inclusion criteria are a pre-treatment diagnosis of axillary lymph node-positive (cN1) disease, confirmed by imaging and typically by biopsy, and a prior axillary evaluation that established this baseline. The current clinical question is strictly the re-evaluation of the axilla to assess treatment response and guide surgical planning.

This workflow is distinct from several related but different clinical situations. It does not apply to:

  • Initial Staging: This article is not for the initial workup of a newly diagnosed breast cancer with a clinically suspicious axilla. That evaluation follows a different diagnostic pathway.
  • Patients who were initially node-negative: If the axilla was clinically and radiologically negative before NST, the post-treatment evaluation strategy is different.
  • Evaluation during therapy: This guidance is for post-treatment assessment, not for interim imaging performed mid-way through a chemotherapy regimen to gauge early response.
  • Evaluation of the primary breast tumor: While the response of the primary tumor is critical, this article focuses specifically on the imaging choice for the axilla. Assessing the breast parenchyma often involves other modalities, like MRI.

Correctly identifying the patient’s stage in the treatment journey—specifically, post-NST and pre-surgery for initially node-positive disease—is essential for applying this recommendation appropriately.

What Diagnoses Are You Working Up in This Scenario?

After neoadjuvant chemotherapy, imaging of the axilla is focused on differentiating between a complete response and residual disease, which has profound implications for prognosis and surgical management. The primary considerations in the differential diagnosis are:

Pathologic Complete Response (pCR) in the Axilla
This is the ideal outcome and the primary goal of neoadjuvant therapy. A pCR means that no viable invasive or in situ carcinoma remains in the axillary lymph nodes. Achieving axillary pCR is associated with a significantly improved prognosis and allows for de-escalation of surgery from a full axillary lymph node dissection (ALND) to a less morbid procedure like sentinel lymph node biopsy (SLNB) combined with targeted axillary dissection (TAD).

Residual Nodal Disease
This is the most consequential finding to identify. It signifies that the chemotherapy was not fully effective in eradicating the cancer from the lymph nodes. The presence of residual disease, even if microscopic, typically necessitates a more extensive surgical procedure (ALND) to ensure regional control and provide accurate prognostic information. Imaging aims to identify suspicious nodes that can be targeted for biopsy or surgical removal.

Post-Treatment Fibrosis and Necrosis
Systemic therapy induces changes in both tumor cells and surrounding tissues. Lymph nodes that previously contained cancer may be replaced by scar tissue (fibrosis) or dead tissue (necrosis). On imaging, these changes can sometimes mimic residual tumor, presenting as hypoechoic, irregularly shaped nodes. Distinguishing these benign post-treatment effects from active disease is a key challenge for the radiologist.

Benign Reactive Lymphadenopathy
The axilla can contain lymph nodes that are enlarged or abnormal-appearing for reasons unrelated to the breast cancer, such as systemic inflammation or infection. While less common in this specific context, it remains a possibility that an abnormal-appearing node is reactive rather than malignant, though any suspicious node in a patient with known nodal metastases is treated as malignant until proven otherwise.

Why Is Axillary Ultrasound the Recommended Study for This Presentation?

For re-evaluating the axilla after neoadjuvant chemotherapy in a patient with known node-positive disease, the ACR designates US axilla as Usually Appropriate. This recommendation is based on the modality’s high spatial resolution, lack of ionizing radiation, and proven utility in guiding subsequent procedures.

Ultrasound provides excellent morphologic detail of lymph nodes. Radiologists assess features such as cortical thickness, the presence or absence of a fatty hilum, overall shape, and vascularity. A node that normalizes in appearance—regaining a thin cortex and a distinct fatty hilum—is suggestive of a good treatment response. Conversely, a node that remains rounded with a thickened, hypoechoic cortex is suspicious for residual disease. This detailed anatomical assessment is precisely what is needed to guide the next step, which is often a biopsy or targeted surgical excision.

Furthermore, if a biopsy clip was placed in the positive node before treatment, ultrasound is the primary tool used to localize that specific clip and the node it marks. This is fundamental to performing a targeted axillary dissection (TAD), a procedure where the sentinel nodes and the clipped node are removed to maximize the accuracy of post-treatment nodal staging.

In contrast, other powerful imaging modalities are rated lower for this specific, focused question:

  • MRI breast without and with IV contrast is rated Usually not appropriate. While breast MRI is the most sensitive tool for assessing response in the primary breast tumor, its performance in the axilla post-NST is more variable. It can be difficult to distinguish post-treatment changes from residual disease, and it does not offer the real-time procedural guidance that ultrasound does.
  • FDG-PET/CT skull base to mid-thigh is also rated Usually not appropriate. This modality carries a high radiation dose (ACR RRL ☢☢☢☢) and is susceptible to false positives from post-treatment inflammation, which can be metabolically active and mimic cancer. Its role is primarily in systemic staging for distant metastases, not for focused morphologic evaluation of the axilla.

The choice of axillary ultrasound is a pragmatic one. It directly answers the clinical question with no radiation exposure (ACR RRL O) and provides the necessary guidance for any subsequent minimally invasive tissue sampling or surgical localization.

What’s Next After Axillary Ultrasound? Downstream Workflow

The results of the post-neoadjuvant axillary ultrasound directly influence the surgical plan and are typically discussed in a multidisciplinary tumor board. The downstream workflow branches based on the findings.

If the ultrasound shows suspicious-appearing nodes:
If one or more lymph nodes (especially the previously clipped node) retain suspicious features (e.g., thickened cortex >2.3 mm, rounded shape, loss of fatty hilum), the next step is often an ultrasound-guided biopsy. A fine-needle aspiration (FNA) or core needle biopsy can confirm the presence of residual metastatic disease. A positive biopsy confirms the need for a full axillary lymph node dissection (ALND) at the time of breast surgery. This avoids the false-negative risk associated with a sentinel node biopsy in this setting.

If the ultrasound shows normal-appearing or absent nodes:
If the previously positive nodes now appear normal or are no longer visible, this suggests a complete or near-complete radiologic response. This patient is now a candidate for surgical de-escalation. The standard of care is evolving, but this typically involves a dual-technique approach: a sentinel lymph node biopsy (SLNB) to evaluate the regional lymphatic basin, combined with a targeted axillary dissection (TAD) to remove the clipped node that was known to be positive pre-treatment. This dual approach has been shown to have a much lower false-negative rate than SLNB alone in this patient population.

If the ultrasound is indeterminate:
Sometimes, post-treatment changes like fibrosis create an equivocal appearance. In these cases, management depends on institutional protocol and multidisciplinary consensus. The surgeon may proceed with SLNB plus TAD, with the understanding that if any of the removed nodes are positive on intraoperative or final pathology, a completion ALND may be necessary.

Pitfalls to Avoid (and When to Get Help)

Navigating post-neoadjuvant axillary imaging requires careful attention to detail to avoid common errors that can impact surgical planning.

  • Failing to review pre-treatment imaging: Always compare the post-treatment ultrasound with the pre-treatment studies to identify the specific node(s) that were initially involved and/or clipped.
  • Not communicating clip placement: The ordering clinician must inform the radiologist that a specific node was clipped, as localizing this marker is a primary goal of the exam.
  • Over-reliance on node size: After chemotherapy, a node can shrink significantly but still harbor microscopic foci of residual cancer. Morphologic features (cortical thickness, hilum) are more reliable indicators than size alone.
  • Difficulty finding the clip: Biopsy clips can migrate or be difficult to visualize, especially amidst post-treatment scarring. Experienced operators may need to use multiple techniques or imaging planes to locate it.

If the ultrasound is technically limited or the findings are discordant with the clinical picture (e.g., a palpable node that appears normal on ultrasound), the case should be escalated for discussion at a multidisciplinary breast cancer conference before proceeding with surgery.

Related ACR Topics and Tools

The decision to order an axillary ultrasound is part of a complex care pathway for breast cancer. For a comprehensive overview of all clinical variants related to imaging after neoadjuvant therapy, and for tools to help with ordering and patient communication, the following resources are available.

Frequently Asked Questions

Why not just go straight to surgery without post-chemotherapy imaging of the axilla?

Imaging the axilla after neoadjuvant chemotherapy is crucial for surgical planning. It helps determine if a patient has had a complete response, which may make them eligible for a less invasive surgery like a sentinel node biopsy instead of a full axillary lymph node dissection. This de-escalation of surgery can significantly reduce the risk of long-term side effects like lymphedema without compromising oncologic outcomes.

What if a biopsy clip was placed in a lymph node before chemo? Does that change the imaging approach?

Yes, it makes the ultrasound even more critical. A primary goal of the post-treatment ultrasound is to locate the clipped node. This allows the surgeon to perform a ‘targeted axillary dissection’ (TAD), where they remove the sentinel nodes plus the specific node that was proven to have cancer before therapy. This technique provides the most accurate assessment of treatment response.

Is MRI better than ultrasound for assessing axillary nodes after chemotherapy?

While breast MRI is superior for evaluating the primary tumor in the breast, the ACR considers ultrasound ‘Usually Appropriate’ and MRI ‘Usually Not Appropriate’ for the specific task of re-evaluating the axilla. Ultrasound offers excellent morphologic detail of the nodes, can guide biopsies in real-time, and is better at localizing the biopsy clip. MRI can be less specific in the axilla, as post-treatment inflammation can mimic residual disease.

If the ultrasound is negative, is there still a chance of residual cancer?

Yes, there is. Ultrasound assesses the morphology (structure) of the lymph nodes, but it cannot detect microscopic disease. A ‘negative’ or ‘normal-appearing’ ultrasound has a false-negative rate. This is why even with a normal post-treatment ultrasound, surgery (typically a sentinel node biopsy plus removal of the clipped node) is still required to pathologically confirm the absence of cancer.

Does this guidance apply to all types of breast cancer?

Yes, this specific imaging recommendation for post-neoadjuvant axillary evaluation applies regardless of the breast cancer subtype (e.g., ER-positive, HER2-positive, or triple-negative). The goal of assessing nodal response to guide surgery is consistent across all subtypes, even though the likelihood of achieving a pathologic complete response may vary.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026